Background:
Whole-body MRI (WB-MRI) including diffusion-weighted image (DWI) have been widely used in patients with multiple myeloma. However, evidence for the value of WB-MRI in the evaluation of treatment response remains sparse. Therefore, we evaluated the role of WB-MRI in the response assessment.
Methods:
In our WB-MRI registry, we searched multiple myeloma patients treated with chemotherapy who underwent both baseline and follow-up WB-MRI scans. Clinical responses were categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), using IMWG criteria. Using RECIST 1.1, MD Anderson (MDA) criteria, and MDA-DWI criteria, imaging responses on WB-MRI were rated as CR, PR, SD, or PD by two radiologists independently. Then, discrepancy cases were resolved by consensus. Weighted Kappa analysis was performed to evaluate agreement between the imaging and clinical responses. The diagnostic accuracy of image responses in the evaluation of clinical CR, objective response (CR and PR), and PD was calculated.
Results:
Forty-two eligible patients were included. There was moderate agreement between imaging and clinical responses (κ = 0.54 for RECIST 1.1, κ = 0.58 for MDA criteria, κ = 0.69 for MDA-DWI criteria). WB-MRI showed excellent diagnostic accuracy in assessment of clinical PD (sensitivity 88.9%, specificity 94.7%, positive predictive value [PPV] 84.2%, negative predictive value [NPV] 96.4% in all three imaging criteria). By contrast, WB-MRI showed low accuracy in assessment of clinical CR (sensitivity 4.5%, specificity 98.1%, PPV 50.0%, NPV 71.2% in all three imaging criteria). As to the clinical objective response, the diagnostic accuracy was higher in MDA-DWI criteria than RECIST 1.1 and MDA criteria (sensitivity/specificity/PPV/NPV, 84.2%/94.4%/98.0%/65.4, 54.4%/100%/100%/40.9, and 61.4%/94.4%/97.2%/43.6%, respectively).
Conclusions:
In the imaging response assessment of multiple myeloma, WB-MRI showed excellent performance in the evaluation of PD, but not in the assessment of CR or objective response. When adding DWI to imaging response criteria, diagnostic accuracy for objective response was improved and agreement between imaging and clinical responses was increased.
Citing Articles
Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring.
Jeong S, Suh C, Kim S, Lemere C, Lim J, Lee J
Korean J Radiol. 2024; 25(8):726-741.
PMID: 39109501
PMC: 11306001.
DOI: 10.3348/kjr.2024.0105.
Imaging of Multiple Myeloma: Present and Future.
Rodriguez-Laval V, Lumbreras-Fernandez B, Aguado-Bueno B, Gomez-Leon N
J Clin Med. 2024; 13(1).
PMID: 38202271
PMC: 10780302.
DOI: 10.3390/jcm13010264.
[Clinical Application and Limitations of Myeloma Response Assessment and Diagnosis System (MY-RADS)].
Kim D, Park S, Jung J
J Korean Soc Radiol. 2023; 84(1):51-74.
PMID: 36818710
PMC: 9935961.
DOI: 10.3348/jksr.2022.0154.
[Imaging for Multiple Myeloma according to the Recent International Myeloma Working Group Guidelines: Analysis of Image Acquisition Techniques and Response Evaluation in Whole-Body MRI according to MY-RADS].
Son A, Chung H
J Korean Soc Radiol. 2023; 84(1):150-169.
PMID: 36818702
PMC: 9935955.
DOI: 10.3348/jksr.2021.0179.
Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI.
Santoni A, Simoncelli M, Franceschini M, Ciofini S, Fredducci S, Caroni F
J Pers Med. 2022; 12(11).
PMID: 36579605
PMC: 9696713.
DOI: 10.3390/jpm12111885.
Modern imaging techniques for monitoring patients with multiple myeloma.
Pop V, Tomoaia G, Parvu A
Med Pharm Rep. 2022; 95(4):377-384.
PMID: 36506611
PMC: 9694753.
DOI: 10.15386/mpr-2215.
Repeatability and test-retest reproducibility of mean apparent diffusion coefficient measurements of focal and diffuse disease in relapsed multiple myeloma at 3T whole body diffusion-weighted MRI (WB-DW-MRI).
Elgendy K, Barwick T, Auner H, Chaidos A, Wallitt K, Sergot A
Br J Radiol. 2022; 95(1138):20220418.
PMID: 35867890
PMC: 9815750.
DOI: 10.1259/bjr.20220418.
Development and validation of an ensemble artificial intelligence model for comprehensive imaging quality check to classify body parts and contrast enhancement.
Na S, Sung Y, Ko Y, Shin Y, Lee J, Ha J
BMC Med Imaging. 2022; 22(1):87.
PMID: 35562705
PMC: 9107169.
DOI: 10.1186/s12880-022-00815-4.
Imaging for Plasma Cell Dyscrasias: What, When, and How?.
Guha A, Vijan A, Agarwal U, Goda J, Mahajan A, Shetty N
Front Oncol. 2022; 12:825394.
PMID: 35402253
PMC: 8987930.
DOI: 10.3389/fonc.2022.825394.
Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis.
Lin G, Zong X, Li Y, Tan W, Sun W, Zhang S
Front Oncol. 2022; 12:827777.
PMID: 35251996
PMC: 8894650.
DOI: 10.3389/fonc.2022.827777.
Modern radiographic imaging in multiple myeloma, what is the minimum requirement?.
Mena E, Turkbey E, Lindenberg L
Semin Oncol. 2022; 49(1):86-93.
PMID: 35190200
PMC: 9149049.
DOI: 10.1053/j.seminoncol.2022.01.007.
Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.
Wang K, Lee E, Kenis S, Hallam S, Haroon A, Wan S
Eur Radiol. 2022; 32(4):2135-2148.
PMID: 35028748
DOI: 10.1007/s00330-021-08311-z.
Radiotherapy Response Assessment of Multiple Myeloma: A Dual-Energy CT Approach With Virtual Non-Calcium Images.
Fervers P, Celik E, Bratke G, Maintz D, Baues C, Ruffing S
Front Oncol. 2021; 11:734819.
PMID: 34646776
PMC: 8504158.
DOI: 10.3389/fonc.2021.734819.
Comprehensive Updates in the Role of Imaging for Multiple Myeloma Management Based on Recent International Guidelines.
Lee K, Kim K, Ko Y, Park H, Chae E, Lee J
Korean J Radiol. 2021; 22(9):1497-1513.
PMID: 34448381
PMC: 8390819.
DOI: 10.3348/kjr.2020.0886.
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Lecouvet F, Vekemans M, Den Berghe T, Verstraete K, Kirchgesner T, Acid S
Skeletal Radiol. 2021; 51(1):59-80.
PMID: 34363522
PMC: 8626399.
DOI: 10.1007/s00256-021-03841-5.
Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma.
Zhang B, Bian B, Zhao Z, Lin F, Zhu Z, Lou M
BMC Med Imaging. 2021; 21(1):98.
PMID: 34103001
PMC: 8186136.
DOI: 10.1186/s12880-021-00631-2.
Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.
Michoux N, Ceranka J, Vandemeulebroucke J, Peeters F, Lu P, Absil J
Eur Radiol. 2021; 31(7):4514-4527.
PMID: 33409773
DOI: 10.1007/s00330-020-07522-0.